{"id":1218,"date":"2020-12-04T07:07:15","date_gmt":"2020-12-04T06:07:15","guid":{"rendered":"https:\/\/ambtokyo.esteri.it\/news\/dall_ambasciata\/2020\/12\/italy-japan-approaches-for-tackling\/"},"modified":"2020-12-04T07:07:15","modified_gmt":"2020-12-04T06:07:15","slug":"italy-japan-approaches-for-tackling","status":"publish","type":"post","link":"https:\/\/ambtokyo.esteri.it\/it\/news\/dall_ambasciata\/2020\/12\/italy-japan-approaches-for-tackling\/","title":{"rendered":"Italy-Japan approaches for tackling the Covid-19 pandemic: an update on novel vaccines and therapies"},"content":{"rendered":"<p style=\"text-align: justify;\">The resurgence of the SARS-Cov-2 infections makes even more urgent the quest for vaccines and therapies. After less than one year from the outbreak of the Covid-19 pandemic, almost 700 vaccines are under study worldwide and about 30 are at least in Phase III of clinical trials, a very advanced stage in such a short time. The aim of this event is to give an update on the situation in Italy and Japan in the field of Covid-19 vaccines and therapies, thus verifying the possibility of collaborations and synergies between the two countries.<\/p>\n<p style=\"text-align: center;\"><em>VENUE: Online on Zoom<\/em><br \/><em>REGISTRATION: <a href=\"https:\/\/zoom.us\/webinar\/register\/WN_POwK6yOORZiJadagH9IPwg\">please click here<\/a><\/em><br \/><em>DATE AND TIME: 9 December 2020, 17.00-19.00 JST (9.00-11.00 CET)<\/em><\/p>\n<p style=\"text-align: justify;\">17.00-17.08 Welcome and Opening Remarks\u00a0\u2013 H.E. <strong>Giorgio Starace<\/strong> (Ambassador of Italy to Japan)<br \/>17.08-17.10 Introduction by the Moderator \u2013 Prof. <strong>Enrico Traversa<\/strong> (Scientific Counsellor, Embassy of Italy)<br \/>17.10-17.30 Japan Keynote on Vaccines \u2013 Prof. <strong>Ryuichi Morishita<\/strong>, Graduate School of Medicine, Osaka University, collaborating with AnGes on clinical trials<br \/>17.30-17.50 Italy Keynote on Vaccines \u2013 Dr. <strong>Alessandra Vitelli<\/strong>, ReiThera, Italian company developing a vaccine in Phase I (currently tested at Ospedale Spallanzani)<br \/>17.50-18.10 Japan Keynote on Therapies \u2013 Dr. <strong>Koichi Watashi<\/strong>, Senior Researcher, Department of Virology II, National Institute of Infectious Diseases<br \/>18.10-18.30 Italy Keynote on Therapies\u00a0\u2013 Dr. <strong>Rino Rappuoli<\/strong>, GSK Vaccines, developing therapy based on monoclonal antibodies<br \/>18.30-19.00 Panel Discussion and Closing Remarks<\/p>\n","protected":false},"excerpt":{"rendered":"The resurgence of the SARS-Cov-2 infections makes even more urgent the quest for vaccines and therapies. After less than one year from the outbreak of the Covid-19 pandemic, almost 700 vaccines are under study worldwide and about 30 are at least in Phase III of clinical trials, a very advanced stage in such a short [&hellip;]","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"tags":[],"class_list":["post-1218","post","type-post","status-publish","format-standard","hentry"],"_links":{"self":[{"href":"https:\/\/ambtokyo.esteri.it\/it\/wp-json\/wp\/v2\/posts\/1218","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ambtokyo.esteri.it\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ambtokyo.esteri.it\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ambtokyo.esteri.it\/it\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ambtokyo.esteri.it\/it\/wp-json\/wp\/v2\/comments?post=1218"}],"version-history":[{"count":0,"href":"https:\/\/ambtokyo.esteri.it\/it\/wp-json\/wp\/v2\/posts\/1218\/revisions"}],"wp:attachment":[{"href":"https:\/\/ambtokyo.esteri.it\/it\/wp-json\/wp\/v2\/media?parent=1218"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ambtokyo.esteri.it\/it\/wp-json\/wp\/v2\/tags?post=1218"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}